Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

NCTNCT01509755 (opens ClinicalTrials.gov in a new tab)Other idNN2211-1310
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
196 participants (estimated)
Sponsor
Novo Nordisk A/S · Industry
Design
Not stated
Countries
4 countries

Denmark, Norway, Sweden, United Kingdom

Start
Oct 2000
Primary completion
Oct 2001
Completion
Oct 2001
First posted
13 Jan 2012 (estimated)
Last update posted
24 Jan 2017 (estimated)
Conditions
Diabetes · Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200020012002
  1. Ph 2

    Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

    NCT01509755

    Oct 2000 to Oct 2001

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

Interventions

  • placeboDrug
  • liraglutideDrug
  • glimepirideDrug

Arms7

  • Placebo comparator

    Placebo

  • Experimental

    0.045 mg

  • Experimental

    0.225 mg

  • Experimental

    0.45 mg

  • Experimental

    0.60 mg

  • Experimental

    0.75 mg

  • Active comparator

    Glim

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. HbA1c (glycosylated haemoglobin)

Secondary outcomes(4)

  1. Fasting plasma glucose

  2. Fructosamine

  3. 7-point blood glucose profile

  4. Adverse events

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2004

7 results

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad et al. 2004Diabetes carecited by 208

PMID 15161785DOI 10.2337/diacare.27.6.1335PUB-15161785

Rights unknown7 results
Source linkSee results (7)

More studies

1 study on this page

Indexing hint: Meta-analysis (pooled) · 2015

Corrected

Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.

Jensen et al. 2015Diabetes carecited by 45

PMID 25504028DOI 10.2337/dc13-1210PUB-25504028

Rights unknown
Source linkRead the notice

Eligibility

Who could join, as posted.

Sex
All
Age
from 30 Years up to 75 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Subjects with type 2 diabetes * Duration of diabetes at least 3 months * Both diet treated and patients in therapy with OHA (oral hypoglycemic agents) * Body Mass Index maximum 40 kg/m\^2 * HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated Exclusion Criteria: * Liver or renal disease * Cardiac problems * Uncontrolled treated/untreated hypertension * Proliferative retinopathy * Recurrent severe hypoglycaemia as judged by the Investigator * Known or suspected allergy to trial product or related products * Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level

PepBank is a research reference. Talk to a doctor before you use any peptide.